Search

Your search keyword '"Latika, Sibal"' showing total 3 results
Start Over Author "Latika, Sibal" Language english
3 results on '"Latika, Sibal"'

1. Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes

Author

Latika Sibal, Sharad C Agarwal, and Philip D Home

Subjects
Specialties of internal medicine, RC581-951
Abstract

Latika Sibal1, Sharad C Agarwal2, Philip D Home21Wolfson Diabetes and Endocrine Clinic, Addenbrooke's Hospital, Cambridge, UK; 2Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UKBackground: Diabetes mellitus is associated with a high risk of cardiovascular disease. Carotid intima-media thickness (CIMT) is increasingly used as a surrogate marker for atherosclerosis. Its use relies on its ability to predict future clinical cardiovascular end points.Methods: This review examines the evidence linking CIMT as a surrogate marker of vascular complications in people with type 1 and type 2 diabetes. We have also reviewed the various treatment strategies which have been shown to influence CIMT.Conclusions: CIMT measurement is an effective, noninvasive tool which can assist in identifying people with diabetes who are at higher risk of developing microvascular and macrovascular complications. It may also help to evaluate the effectiveness of various treatment strategies used to treat people with diabetes.Keywords: carotid, intima-media thickness, CIMT, diabetes

Published
2011

2. Management of type 2 diabetes: NICE guidelines

Author

Philip Home and Latika Sibal

Subjects
medicine.medical_specialty, business.industry, media_common.quotation_subject, Conference Reports, education, MEDLINE, Nice, Subject (documents), General Medicine, Guideline, Type 2 diabetes, medicine.disease, Excellence, Family medicine, Medicine, business, computer, media_common, computer.programming_language
Abstract

The National Institute for Health and Clinical Excellence (NICE) guideline on the management of type 2 diabetes, prepared by the Royal College of Physicians (RCP),[1][1] was the subject of a conference at the College in June 2008. This report highlights some themes of that meeting, concentrating on

Published
2009

3. A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuria

Author

S.C. Agarwal, Edzard Schwedhelm, Philip Home, Nicole Lüneburg, Latika Sibal, and Rainer H. Böger

Subjects
Adult, Male, medicine.medical_specialty, lcsh:Diseases of the circulatory (Cardiovascular) system, Adolescent, Brachial Artery, Nitric Oxide Synthase Type III, Endocrinology, Diabetes and Metabolism, Arginine, Nephropathy, chemistry.chemical_compound, Young Adult, Risk Factors, Internal medicine, Diabetes mellitus, medicine, Albuminuria, Humans, Endothelial dysfunction, Macrovascular disease, Ultrasonography, Original Investigation, Type 1 diabetes, medicine.diagnostic_test, business.industry, medicine.disease, Vasodilation, Endocrinology, Diabetes Mellitus, Type 1, chemistry, lcsh:RC666-701, Case-Control Studies, Microalbuminuria, Female, Endothelium, Vascular, Cardiology and Cardiovascular Medicine, Lipid profile, business, Asymmetric dimethylarginine, Cell Adhesion Molecules, Biomarkers, Diabetic Angiopathies
Abstract

Background Asymmetric dimethylarginine (ADMA) is a competitive inhibitor of endothelial nitric oxide synthase (eNOS) that is associated with endothelial dysfunction, and is a risk marker for cardiovascular disease, a significant problem in Type 1 diabetes. The aim of the present study was to measure circulating ADMA, and define its association with endothelial dysfunction and endothelial markers in people with Type 1 diabetes with low likelihood of macrovascular disease. Methods Sixty-one young people with Type 1 diabetes without macrovascular disease or nephropathy and 62 healthy volunteers underwent brachial artery flow-mediated dilatation (FMD) and assay of plasma ADMA and adhesion molecules. Results Age, gender, BMI, lipid profile and renal function were similar in the two groups. People with Type 1 diabetes had impaired FMD compared to healthy controls (5.0 ± 0.4 vs 8.9 ± 0.4%; p < 0.001). Plasma ADMA levels were significantly lower in the people with diabetes compared to healthy controls (0.52 ± 0.12 vs 0.66 ± 0.20 μmol/l, p < 0.001). Plasma ICAM-1, E-selectin and PAI-1 levels were significantly higher in people with diabetes compared to healthy controls (median 201 (IQR 172–226) vs 180 (156–216) μg/l, p = 0.027; 44.2 (32.6–60.9) vs. 33.1 (22.4–51.0) μg/l; p = 0.003 and 70.8 (33.3–85.5) vs 46.3 (23.9–76.8) μg/l, p = 0.035). Plasma ADMA and VCAM-1 levels were positively correlated (r = 0.37, p = 0.003) in people with diabetes. There was no correlation between the plasma ADMA and FMD. Conclusion ADMA levels are not associated with endothelial dysfunction in young adults with Type 1 diabetes without microalbuminuria or known macrovascular disease. This suggests that the impaired endothelial function in these individuals is not a result of eNOS inhibition by ADMA.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results